- IntelGenx Technologies (IGX) has received approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange
- The company’s shares, convertible debentures and share purchase warrants are expected to commence trading on the TSX at market open on Thursday and will be delisted from the TSXV
- The graduation will help IntelGenx develop a stronger profile within the investment community
- IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films
- IntelGenx Technologies Corp. (IGX) is down 6.67 per cent, trading at C$0.56 per share at 2:40 pm ET
IntelGenx Technologies (IGX) has received approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange.
The company’s shares, convertible debentures and share purchase warrants are expected to commence trading on the TSX at market open on Thursday, October 7 under the existing stock symbols and will be delisted from the TSXV.
Dr. Horst G. Zerbe, CEO of IntelGenx commented on the uplisting.
“The TSX is Canada’s most prestigious and senior exchange. This graduation marks an important milestone for IntelGenx, and we believe that it will help us develop a stronger profile in the investment community.”
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx Technologies Corp. (IGX) is down 6.67 per cent, trading at C$0.56 per share at 2:40 pm ET.
